DONGKOOK Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
March 12, 2015
Share
DONGKOOK Pharmaceutical Co., Ltd. (KOSDAQ:A086450) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5000 million pursuant to a trust contract with Woori Investment & Securities Co. Ltd. The purpose of the share repurchase program is to stabilize the company's share price and to enhance shareholder value.
The share repurchase program is valid until September 13, 2015. As of March 12, 2015, the company had 98,446 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
DONGKOOK PHARMACEUTICAL CO., LTD. 
